Company intelligence / Profile preview

Epigen Pharmaceuticals

San Diego, California, United Statesir.tonixpharma.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

All pipeline programs are in preclinical development. Lead asset EPGN696, a selective LPA1 antagonist for diabetic kidney disease and related indications, was licensed to Novo Nordisk in a deal worth up to $200 million. Other assets include small molecules targeting Sigma1R for neurodegenerative diseases and p70S6K inhibitors for Fragile X syndrome. No clinical results have been reported yet.

Therapeutic areas: NephrologyGastroenterologyPulmonologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Novo Nordisk (licensee of EPGN696 program)

Beyond the preview

Go deeper on Epigen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epigen Pharmaceuticals.

Explore the full profile